Whether its working with Pharmaceutical, CRO or Biotech organisations, within the disciplines of Clinical Development, Operations & Outsourcing, Regulatory Affairs, Biometrics, Healthcare, Drug Safety, R&D, Medical Affairs & Communications, QA/QC, Manufacturing & Engineering or Health Economics, SEC Pharma can assist wherever you are looking to hire or work throughout the UK and Europe.
Established in 2000, SEC Pharma consists of a team of multi-lingual and highly experienced consultants who each have a background in clinical or scientific disciplines and know their markets extremely well. Our consultants work from our offices in London and Woking in the UK, as well as Munich, Zug and Singapore however each one has a focus on a particular skill set and specific geography, depending on their technical knowledge, cultural awareness and language skills.
By familiarising ourselves with individual candidate skill sets and personalities, as well as our client’s specific business requirements and cultures, we guarantee we can match jobseekers with client roles – ensuring both organisation and individual can work to their full potential, wherever they are located. We have successfully recruited in Belgium, UK, Netherlands, France, Germany, Switzerland, Spain, Italy, Poland, Denmark, Sweden and Norway.
SEC latest news
SEC Pharma Joins Forces with IAOCRAugust 12, 2014 - SEC Pharma is delighted to announce that we have joined forces with IAOCR to provide innovative solutions to recruiting, developing and retaining clinical research professionals. IAOCR provides training, accreditation and consultancy services to pharmaceutical, biotech and clinical research organisations and is one of the only organisations in the world to provide independently verified and
Roche to Acquire Santaris PharmaAugust 7, 2014 - Roche has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company as part of its plan to expand discovery and development of RNA-targeting medicines. Santaris has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics. This new class of medicines has the potential to address